Safety/Acuity Outcomes 96-Weeks Post-Treatment with rAAV2/2-ND4; Gene Therapy for ND4 LHON: a Phase I/II Trial
Your browser does not support the video tag.
Identifier
20180305_nanos_sciplatform1_08
Title
Safety/Acuity Outcomes 96-Weeks Post-Treatment with rAAV2/2-ND4; Gene Therapy for ND4 LHON: a Phase I/II Trial
Creator
Barrett Katz, Catherine Vignal, Celine Bouquet, Nitza Thomasson, Ann Galy, Serge Fitoussi, Jose Sahel
Subject
Optic Neuropathy, Genetic Disease, LHON, Gene Therapy
Description
rAAV2/2-ND4 is an investigational gene therapy enabling allotopic transgene expression. We report safety and visual acuity outcomes 96 weeks post-treatment in a Phase I/II open-label dose escalation trial.
Date
2018-04
Language
eng
Format
video/mp4
Source
2018 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2018: Scientific Platform, Session I
Collection
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher
Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management
Copyright 2018. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK
ark:/87278/s6zh0vn7
Context URL
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Contributor Primary
Barrett Katz
Contributor Secondary
Catherine Vignal, Celine Bouquet, Nitza Thomasson, Ann Galy, Serge Fitoussi, Jose Sahel
Setname
ehsl_novel_nam
ID
1316070
Reference URL
https://collections.lib.utah.edu/ark:/87278/s6zh0vn7